Jiangsu

Who we are

  • April 5, 2022
    Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer
  • January 1, 1970
    Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM